Characterization of recombinant factor IX fusion proteins enabling subcutaneous administration.

Abstract excerpt

BACKGROUND: The X-linked bleeding disorder hemophilia B, caused by mutation(s) in the coagulation factor (F)IX gene, leads to partial or total loss of its function, requiring lifelong FIX replacement therapy. Although new recombinant FIX (rIX) therapeutics like albumin fusion proteins (rIX-FP) enable longer plasma half-life and thus less frequent administration, the complexity of intravenous (i.v.) injection...

Topics

Join the communities discussing this publication.

• Coagulants
• Factor IX
• Half-Life
• Hemophilia B
• Hemorrhage